Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene

Maturitas ◽  
2005 ◽  
Vol 50 (4) ◽  
pp. 321-330 ◽  
Author(s):  
G. Christodoulakos ◽  
I. Lambrinoudaki ◽  
C. Panoulis ◽  
V. Sioulas ◽  
D. Rizos ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Androgen Levels

scholarly journals The effects of low dose hormone therapy on serum lipid profile, glisemic control, thyroid hormones and androgen levels in postmenopausal women

2011 ◽  
Vol 8 (2) ◽  
pp. 125-133
Author(s):  
A Yasemin Karageyim Karsidag ◽  
Nevriye Alkan ◽  
Esra Esim Buyukbayrak ◽  
Bulent Kars ◽  
Meltem Pirimoglu ◽  
...  
Keyword(s):  
Thyroid Hormones ◽  
Hormone Therapy ◽  
Lipid Profile ◽  
Postmenopausal Women ◽  
Serum Lipid ◽  
Low Dose ◽  
Serum Lipid Profile ◽  
Androgen Levels

Androgens and cardiovascular risk

2012 ◽  
Vol 0 (0) ◽  
pp. 1-9
Author(s):  
Elisabeth Lerchbaum
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Postmenopausal Women ◽  
Clinical Signs ◽  
The Metabolic Syndrome ◽  
Age Related ◽  
The Impact ◽  
Androgen Levels

AbstractTestosterone concentrations in men gradually decrease with age. Whether this reduction in androgen levels is a pathological process or a physiological event remains to be determined. The age-related decrease in testosterone levels is, however, frequently accompanied by adverse health consequences including low bone and muscle mass, increased fat mass, type 2 diabetes mellitus and the metabolic syndrome. Moreover, low androgen levels are associated with increased mortality. Testosterone treatment should be performed in men with low androgen levels as well as clinical signs and symptoms of hypogonadism. In premenopausal women, hyperandrogenemia is associated with several cardiovascular risk factors. The most common cause of hyperandrogenemia in women is polycystic ovary syndrome (PCOS). PCOS women are affected by hyperandrogenism, infertility and metabolic disturbances, such as insulin resistance, central obesity and dyslipidemia. Androgen levels decrease with menopausal transition in women. Hyperandrogenemia is associated with insulin resistance and type 2 diabetes in postmenopausal women. Whether this hyperandrogenemia results in increased mortality is, however, less clear. Moreover, the impact of androgen supplementation in postmenopausal women with hypoandrogenemia is open.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document